FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
KELLER WILLIAM R					ALXN]							X Directo	r	10% O	vner		
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE												Officer below)	(give title	Other (sbelow)	specify		
					3. Date of Earliest Transaction (Month/Day/Year) 05/05/2014												
						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)											Line	•	led by One Rep	orting Perso	,		
CHESHI	RE C	Γ	06410									Form fi	led by More tha	Ü	I		
(City)	(S	tate)	(Zip)									Persor					
		•															
		Tal	ole I - Non-De	rivativ	e Se	curities	Ac	quired, Di	sposed o	f, or Ber	neficiall	y Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				•	/ear)	Execution if any	A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			5. Amoui Securitie Beneficia Owned F	Form ly (D) or	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																
								, options,				Ownea					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Exercise (Month/Day/Year) if any (Month/Day/Year) rivative		4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Option to Purchase Common Stock	\$159.7	05/05/2014		A		2,785 <sup>(1)</sup>		05/05/2015	05/05/2024	Common Stock, par value \$.0001 per share	2,785	\$159.7	2,785	D			

#### **Explanation of Responses:**

1. Stock options vest on the first anniversary of the grant date.

### Remarks:

/s/ Michael V. Greco, Attorneyin-Fact 05/07/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.